PMID- 22241467
OWN - NLM
STAT- MEDLINE
DCOM- 20120501
LR  - 20211021
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 17
IP  - 1
DP  - 2012 Jan 12
TI  - Evaluation of the immunity activity of glycyrrhizin in AR mice.
PG  - 716-27
LID - 10.3390/molecules17010716 [doi]
AB  - In this study, we evaluated effect of glycyrrhizin on immunity function in 
      allergic rhinitis (AR) mice. The AR mice model were induced by dripping ovalbumin 
      in physiological saline (2 mg mL(-)(1), 10 muL) into the bilateral nasal cavities 
      using a micropipette. After the AR model was induced, mice were randomly divided 
      into six groups: the normal control, model, lycopene 20 mg kg(-)(1) (as positive 
      control drug) group, and glycyrrhizin 10, 20, 30 mg kg(-)(1) groups. After the 
      sensitization day 14, lycopene (20 mg/kg BW) and glycyrrhizin (10, 20 and 30 
      mg/kg BW) were given orally for 20 days once a day. Mice in the normal control 
      and model groups were given saline orally once a day for 20 days. Results showed 
      that glycyrrhizin treatment could dose-dependently significantly reduce blood 
      immunoglobulin E (IgE), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 
      (IL-6), nitrous oxide (NO), tumor necrosis factor-alpha (TNF-alpha) levels and 
      nitrous oxide synthase (NOS) activity and enhance blood immunoglobulin A (IgA), 
      immunoglobulin G (IgG), immunoglobulin M (IgM), interleukin-2 (IL-2) and 
      interleukin-12 (IL-12) levels in AR mice. Furthermore, glycyrrhizin treatment 
      could dose-dependently significantly enhance acetylcholinesterase (AchE) activity 
      and reduce substance P (SP) level in peripheral blood and nasal mucosa of AR 
      mice. We conclude that glycyrrhizin can improve immunity function in AR mice, 
      suggesting a potential drug for the prevention and therapy of AR.
FAU - Li, Xiao-Lan
AU  - Li XL
AD  - Ear-Nose-Throat Department of the 1st Hospital Associated to the ShiHeZi 
      University, ShiHeZi City 832008, XinJiang, China. lixlsdoc158@yahoo.com.cn
FAU - Zhou, Ai-Guo
AU  - Zhou AG
LA  - eng
PT  - Journal Article
DEP - 20120112
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 33507-63-0 (Substance P)
RN  - 6FO62043WK (Glycyrrhizic Acid)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 3.1.1.7 (Acetylcholinesterase)
SB  - IM
MH  - Acetylcholinesterase/metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Glycyrrhizic Acid/*pharmacology/therapeutic use
MH  - Immunoglobulins/blood
MH  - Interleukins/blood
MH  - Male
MH  - Mice
MH  - Nasal Mucosa/drug effects/enzymology/metabolism
MH  - Nitric Oxide/blood
MH  - Nitric Oxide Synthase/blood
MH  - Ovalbumin
MH  - Random Allocation
MH  - Rats
MH  - Rhinitis, Allergic, Perennial/blood/chemically induced/drug therapy/*immunology
MH  - Substance P/blood/metabolism
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC6268580
EDAT- 2012/01/14 06:00
MHDA- 2012/05/02 06:00
PMCR- 2012/01/12
CRDT- 2012/01/14 06:00
PHST- 2011/12/12 00:00 [received]
PHST- 2011/12/29 00:00 [revised]
PHST- 2011/12/29 00:00 [accepted]
PHST- 2012/01/14 06:00 [entrez]
PHST- 2012/01/14 06:00 [pubmed]
PHST- 2012/05/02 06:00 [medline]
PHST- 2012/01/12 00:00 [pmc-release]
AID - molecules17010716 [pii]
AID - molecules-17-00716 [pii]
AID - 10.3390/molecules17010716 [doi]
PST - epublish
SO  - Molecules. 2012 Jan 12;17(1):716-27. doi: 10.3390/molecules17010716.